The Effect of Atorvastatin and Continuous Aerobic Exercise on the Expression of Vascular Endothelial Growth Factor Beta Gene in the Liver Tissue of Diabetic Rats

Document Type : Original Article


1 Department of Sports Physiology, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran.

2 Department of Sports Physiology, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran

3 Department of Sports Physiology, Sari Branch, Islamic Azad University, Sari, Iran.


Background and Objectives Contrary to its weak role in angiogenesis, vascular endothelial growth factor beta (VEGF-β) plays a role in lipid metabolism. The aim of this study was to determine the effect of exercise and atorvastatin on the expression of the VEGF-β gene in the liver tissue of diabetic rats. Subjects and Methods In this study, 25 rats were divided into control, diabetes, diabetes + exercise, diabetes + atorvastatin, and diabetes + atorvastatin + exercise groups. The interventions included eight weeks of aerobic exercise, running on a treadmill, and taking 10 mg of atorvastatin by gavage. After the interventions, the rats were sacrificed, and the liver tissue was analyzed. Statistical analysis was performed using one-way analysis of variance and LSD post hoc test. Results The results showed that the induction of diabetes led to a significant decrease in hepatic VEGF-β gene expression and an increase in serum glucose and total cholesterol levels compared to the healthy control group. In the diabetes + exercise and diabetes + atorvastatin + exercise groups, the increase of VEGF-β and the decrease of glucose and cholesterol were significant compared to the control, diabetes, and diabetes + atorvastatin groups. Conclusion According to the results, it can be argued that continuous aerobic exercise can prevent diabetes-induced liver complications by increasing the expression of VEGF-β gene. However, despite the positive effects of atorvastatin on serum glucose and total cholesterol levels, it does not have any significant effect on hepatic VEGF-β gene expression in diabetic rats.


Main Subjects

[1] Ghalavand A, Delaramnasab M, Ghanaati S. Comparison of the effect of telenursing and aerobic training on cardiometabolic and anthropometric indices in patients with type 2 diabetes. Razi Journal of Medical Sciences. 2021 Jul 10;28(4):34-45. [Link]
[2] Amanat S, Ghahri S, Dianatinasab A, Fararouei M, Dianatinasab M. Exercise and Type 2 Diabetes. Physical Exercise for Human Health, 91–105. [10.1007/978-981-15-1792-1_6 ] [PMID]
[3] Fralick M, Jenkins AJ, Khunti K, Mbanya JC, Mohan V, Schmidt MI. Global accessibility of therapeutics for diabetes mellitus. Nature Reviews Endocrinology. 2022 Apr;18(4):199-204.
[10.1038/s41574-021-00621-y ] [PMID]
[4] Fang C, Pan J, Qu N, Lei Y, Han J, Zhang J, Han D. The AMPK pathway in fatty liver disease. Frontiers in Physiology. 2022 Aug 25;13:970292. [10.3389/fphys.2022.970292 ] [PMID]
[5] Memaj P, Jornayvaz FR. Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology. Frontiers in Endocrinology. 2022 Dec 1;13:1031633. [10.3389/fendo.2022. 1031633 ] [PMID]
[6] Jokar M, Ghalavand A. The effect of twelve weeks of aerobic interval training on liver complications and cardiovascular risk factors in men with type 2 diabetes. Razi Journal of Medical Sciences. 2022 May 10;29(3):26-36. [Link]
[7] Li YQ, Xin L, Zhao YC, Li SQ, Li YN. Role of vascular endothelial growth factor B in nonalcoholic fatty liver disease and its potential value. World Journal of Hepatology. 2023 Jun 6;15(6):786. [10.4254/wjh.v15.i6.786 ] [PMID]
[8] Mohammadi F, Ghalavand A, Delaramnasab M. Effect of circuit resistance training and L-carnitine supplementation on body composition and liver function in men with non-alcoholic fatty liver disease. Jundishapur Journal of Chronic Disease Care. 2019 Oct 31;8(4). [10.5812/jjcdc.90213] [Link]
[9] Bry M, Kivelä R, Leppänen VM, Alitalo K. Vascular endothelial growth factor-B in physiology and disease. Physiological reviews. 2014 Jul;94(3):779-94. [10.1152/physrev.00028.2013 ] [PMID]
[10] Alkhouri N, Carter-Kent C, Feldstein AE. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert review of gastroenterology & hepatology. 2011 Apr 1;5(2):201-12. [10.1586/egh.11.6 ] [PMID]
[11] Lal N, Chiu AP, Wang F, Zhang D, Jia J, Wan A, Vlodavsky I, Hussein B, Rodrigues B. Loss of VEGFB and its signaling in the diabetic heart is associated with increased cell death signaling. American Journal of Physiology-Heart and Circulatory Physiology. 2017 Jun 1;312(6):H1163-75. [10.1152/ajpheart. 00659.2016 ] [PMID]
[12] Ghalavand A, Behzadinejad H, Movahedrad S, Maleki F, Rhmani Ghobadi M, Fathi K, Mirpour Shirkhoda S. Relationship between quality of life and cardiorespiratory endurance in patients with type 2 diabetes. Razi Journal of Medical Sciences. 2022 Dec 10;29(9):75-85 [Link]
[13] Ghalavand A, Motamedi P, Rajabi H, Khaledi N. The effect of six weeks aerobic training on Serum and muscle levels of ascorbic acid and SVCT2 of soleus muscle tissue in Wistar rats. Jundishapur Scientific Medical Journal. 2019 Jan 21;17(5):481-90. [10.22118/jsmj.2019.161084.1546] [Link]
[14] Ghalavand A, Ghobadi MR. Effect of Exercise and Insulin Signaling on Glucose Transporter Type 4 in Skeletal Muscles: A narrative review. Journal of Shahid Sadoughi University of Medical Sciences. 2023 Mar 27. [Link]
[15] Ghalavand A, Motamedi P, Rajabi H, Khaledi N. Effect of diabetes induction and exercisetraining on the level of ascorbic acid and muscle SVCT2 in male Wistar rats. Journal of Shahid Sadoughi University of Medical Sciences. 2020 May 19. [10.18502/ssu.v27i12.2831 ] [PMID]
[16] Ghalavand A, Mohammadpour M, RahmaniGhobadi M, Motamedi P, Hovsepian A. Changes in the serum levels of metabotropic biomarkers (asprosin and BDNF) in adapting to intermittent aerobic training. Ilam. 2023; 31 (2): 86-96. [Link]
[17] Alvarez-Jimenez L, Morales-Palomo F, Moreno-Cabañas A, Ortega JF, Mora-Rodríguez R. Effects of statin therapy on glycemic control and insulin resistance: A systematic review and meta-analysis. European Journal of Pharmacology. 2023 Mar 24:175672. [10.1016/j.ejphar.2023.175672 ] [PMID]
[18] Yang X, Xiong T, Ning D, Wang T, Zhong H, Tang S, Mao Y, Zhu G, Wang D. Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity. Toxicology and Applied Pharmacology. 2020 Sep 1;402:115132. [10.1016/j.taap.2020.115132 ] [PMID]
[19] Clarke AT, Mills PR. Atorvastatin associated liver disease. Digestive and liver disease. 2006 Oct 1;38(10):772-7. [10.1016/ j.dld.2006.04.013] [Link]
[20] Rasht I. The Interaction Effect of Aerobic Exercise and Atorvastatin Consumption on the expression level of MFN1/2 and DRP1 in Hepatocytes of the Rat Liver with Type 2 Diabetes. Journal of Ardabil University of Medical Sciences. 2022; 21(4):388-401. [10.52547/jarums.21.4.388 ] [Link]
[21] Maboune N, Fonkoua M, Goda D, Ngoumen DJ, Nanhah JK, Akamba BD, Chedjou JP, Nguedjo MW, Ella FA, Mbah JL, Nguemto GR. Autranella congolensis Extract Prevents Atherogenic Dyslipidemia in Diabetic Rats via Modulation of Global Hepatic DNA Methylation. American Journal of Biomedical and Life Sciences. 2023;11(3):53-9. [10.11648/j. ajbls.20231103.14][Link]
[22] Li R, Li Y, Yang X, Hu Y, Yu H, Li Y. Reducing VEGFB accelerates NAFLD and insulin resistance in mice via inhibiting AMPK signaling pathway. Journal of Translational Medicine. 2022 Jul 30;20(1):341. [10.1186/s12967-022-03540-2] [PMID]
[23] Ye X, Kong W, Zafar MI, Zeng J, Yang R, Chen LL. Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction. EXCLI journal. 2020;19:1186. [10.17179/excli2020-2647 ] [PMID]
[24] Kivelä R, Silvennoinen M, Lehti M, Jalava S, Vihko V, Kainulainen H. Exercise-induced expression of angiogenic growth factors in skeletal muscle and in capillaries of healthy and diabetic mice. Cardiovascular diabetology. 2008 Dec;7:1-0. [10.1186/1475-2840-7-13 ] [PMID]
[25] Luo X, Li RR, Li YQ, Yu HP, Yu HN, Jiang WG, Li YN. Reducing VEGFB expression regulates the balance of glucose and lipid metabolism in mice via VEGFR1. Molecular Medicine Reports. 2022 Sep 1;26(3):1-5. [10.3892/mmr.2022.12801] [PMID]
Journal of Medical Sciences
July & August 2023. Vol 22. No 3
Ahmedpour S, et al. Atorvastatin and Continuous Aerobic Exercise on the Expression of Vascular Endothelial Growth Factor Beta Gene. JSMJ. 2023;
22(3): 354-365
[26] Mehlem A, Palombo I, Wang X, Hagberg CE, Eriksson U, Falkevall A. PGC-1α coordinates mitochondrial respiratory capacity and muscular fatty acid uptake via regulation of VEGF-B. Diabetes. 2016 Apr 1;65(4):861-73. [10.2337/db15-1231 ] [PMID]
[27] Lira VA, Benton CR, Yan Z, Bonen A. PGC-1α regulation by exercise training and its influences on muscle function and insulin sensitivity. American Journal of Physiology-Endocrinology and Metabolism. 2010 Aug;299(2):E145-61. [10.1152/ajpendo.00755.2009 ] [PMID]
[28] Haase TN, Ringholm S, Leick L, Biensø RS, Kiilerich K, Johansen S, Nielsen MM, Wojtaszewski JF, Hidalgo J, Pedersen PA, Pilegaard H. Role of PGC-1α in exercise and fasting-induced adaptations in mouse liver. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2011 Nov;301(5):R1501-9. [10.1152/ajpregu.00775.2010 ] [PMID]
[29] Spaulding HR, Yan Z. AMPK and the adaptation to exercise. Annual Review of Physiology. 2022 Feb 10;84:209-27. [10.1146/annurev-physiol-060721-095517 ] [PMID]
[30] Machado MV. Aerobic exercise in the management of metabolic dysfunction associated fatty liver disease. Diabetes, Metabolic Syndrome and Obesity. 2021 Aug 11:3627-45. [10.2147/DMSO.S304357] [PMID]
[31] Gao Y, Zhang W, Zeng LQ, Bai H, Li J, Zhou J, Zhou GY, Fang CW, Wang F, Qin XJ. Exercise and dietary intervention ameliorate high-fat diet-induced NAFLD and liver aging by inducing lipophagy. Redox biology. 2020 Sep 1;36:101635.
[10.1016/j.redox.2020.101635 ] [PMID]
[32] .Zou Y, Chen Z, Sun C, Yang D, Zhou Z, Peng X, Zheng L, Tang C. Exercise intervention mitigates pathological liver changes in NAFLD zebrafish by activating SIRT1/AMPK/NRF2 signaling. International Journal of Molecular Sciences. 2021 Oct 10;22(20):10940. [10.3390/ijms222010940 ] [PMID]
[33] Spadaccio C, Pollari F, Casacalenda A, Alfano G, Genovese J, Covino E, Chello M. Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study. Journal of cardiovascular pharmacology. 2010 Jan 1;55(1):30-8. [10.1097/FJC.0b013e 3181c37d4d ] [PMID]
[34] Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. The Lancet. 2004 Aug 21;364(9435):685-96. [10.1016/S0140-6736(04)168 95-5 ] [PMID]
[35] Pastori D, Pani A, Di Rocco A, Menichelli D, Gazzaniga G, Farcomeni A, D'Erasmo L, Angelico F, Del Ben M, Baratta F. Statin liver safety in non‐alcoholic fatty liver disease: A systematic review and metanalysis. British Journal of Clinical Pharmacology. 2022 Feb;88(2):441-51. [10.1111/bcp.14943 ] [PMID]
[36] Torrado-Salmerón C, Guarnizo-Herrero V, Henriques J, Seiça R, Sena CM, Torrado-Santiago S. Multiparticulate Systems of Ezetimibe Micellar System and Atorvastatin Solid Dispersion Efficacy of Low-Dose Ezetimibe/Atorvastatin on High-Fat Diet-Induced Hyperlipidemia and Hepatic Steatosis in Diabetic Rats.
Pharmaceutics. 2021 Mar 20;13(3):421. [10.3390/pharma ceutics13030421 ] [PMID]